Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Breast Cancer: early-phase trial registry
74 of 140 indexed Metastatic Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #82 of 28,707 conditions by registered trial count.
140 US clinical trials · 74 currently recruiting · #82 of 28,707 conditions by registered trial count
Metastatic Breast Cancer: 140 US clinical trials tracked, 74 recruiting.
Metastatic Breast Cancer is the subject of 140 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition metastatic-breast-cancer
OPEN 74 | RECR 53% | LATE 11 | EARLY 99 | RANK #82 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Solid Tumor (53% recruiting · 197 trials)
Metastatic Breast Cancer lists 74 open slots (53% of 140 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Breast Cancer is recruiting above its size-band peers.
74 of 140 indexed trials (52.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 12 of 140 trials (8.6%). 93 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Breast Cancer enrolment sits around 71 participants.
Median target enrolment is 71 among the 140 trials that report a genuine target (sentinel values excluded). 78 of those (55.7%) plan for fewer than 100 participants.
-
Metastatic Breast Cancer research is mostly interventional.
128 interventional and 12 observational studies make up this index (91.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
140 total, page 2 of 3
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
Mayo Clinic
NCT06055881
HER-2 B Cell Peptide Vaccine
Pravin T.P Kaumaya
NCT06414733
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
NCT03449238
Adaptation of a Values Assessment Tool
UNC Lineberger Comprehensive Cancer Center
NCT07068477
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05534438
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
University of Alabama at Birmingham
NCT06105684
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Dartmouth-Hitchcock Medical Center
NCT05716516
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
The Methodist Hospital Research Institute
NCT05660083
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Mayo Clinic
NCT06525766
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
University of Utah
NCT04315233
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04683679
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
University of Texas Southwestern Medical Center
NCT05029999
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06246968
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06557148
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06678269
Definitive Radiation for High-Risk Spine Metastases
Stony Brook University
NCT06165419
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
NCT05524584
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Wake Forest University Health Sciences
NCT02422641
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06409390
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
UNC Lineberger Comprehensive Cancer Center
NCT05440929
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
University of Louisville
NCT04990921
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
NCT04573231
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
University of California, San Francisco
NCT05964504
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
Mary D Chamberlin
NCT05900895
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States
Boehringer Ingelheim
NCT07342309
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio
NCT06018337
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Eli Lilly and Company
NCT04188548
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
SOLTI Breast Cancer Research Group
NCT05207709
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
AstraZeneca
NCT04538742
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Eli Lilly and Company
NCT02747004
Palbociclib After CDK and Endocrine Therapy (PACE)
Dana-Farber Cancer Institute
NCT03147287
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02965755
PhII ICb With/Without Erbitux in MBC Pts
US Oncology Research
NCT00248287
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
AstraZeneca
NCT04556773
Roll-over Study to Allow Continued Access to Ribociclib
Novartis Pharmaceuticals
NCT05161195
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
Olaparib In Metastatic Breast Cancer
Beth Israel Deaconess Medical Center
NCT03344965
Couples' QOL in Metastatic Breast Cancer
Fox Chase Cancer Center
NCT05636943
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Ana C Garrido-Castro, MD
NCT04448886
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Dana-Farber Cancer Institute
NCT05721248
Assessing the Time Demands of Cancer
Masonic Cancer Center, University of Minnesota
NCT05708703
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
Menarini Silicon Biosystems
NCT05662345
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
Stemline Therapeutics
NCT05596409
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02738866
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
University of Alabama at Birmingham
NCT03368729
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
University of Maryland, Baltimore
NCT05968144
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
NCT05826964
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
University of Virginia
NCT03272334
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
University of Pennsylvania
NCT02608216
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 52 |
| Phase 3 | 10 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Breast Cancer page
140 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Metastatic Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Metastatic Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Breast Cancer condition card totals 140 registered trials; most-linked intervention Fulvestrant; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.